$22.47 $0.24 per serving
Product analysis
Super K offers affordable vitamin K to support proteins involved in normal bone mineral handling.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality27
The vitamin K form is not clearly disclosed in the ingredient breakdown, limiting a complete quality comparison. Vitamin C has a named form, but its relative quality also remains uncertain.
Ingredient Transparency81
Both nutrient amounts are stated. Vitamin C has a named form, while vitamin K lacks a clearly disclosed form in the ingredient breakdown.
Value For Money78
The low serving cost offers good value for vitamin K. Whether vitamin C adds meaningful value remains uncertain.
Customer Satisfaction91
Customer ratings are very positive. The large review history gives an established picture of satisfaction, without proving health effects.
Product Focus57
The clearest role is vitamin K nutrition for proteins involved in bone mineral handling. Findings for particular MK-7 preparations do not establish the same vascular or longevity benefits for the combined vitamin K forms.
- Format
Softgel - Container
- 90 Softgel(s)
- Per serving
- $0.24
- Also available
Low Dose Vitamin K2 (MK-7) 45 mcg$13.50- Customer rating
- 4.7 · 13,387 ratings
Goals
Impact
Moderate effect
Vitamin K · 2600 mcg
Vitamin K has limited preparation-specific evidence for selected measures of arterial stiffness. The supplied forms include K1, MK-4 and MK-7, whose amounts and identities must be assessed separately; a combined vitamin K total cannot substitute for the studied MK-7 exposure.
How this product is rated for Heart Health
Ingredient fit58
The saved findings identify 1 relevant ingredients and 1 other active ingredients (Vitamin C). Other linked uses also affect focus. The evaluated amounts only partly meet the saved dose benchmarks.
Goal fit
The saved findings identify 1 relevant ingredients and 1 other active ingredients (Vitamin C). Other linked uses also affect focus.
Dose adequacy
The evaluated amounts only partly meet the saved dose benchmarks.
Pathways19
The strongest recorded connection is to arterial calcification control, with limited coverage. None of the listed processes reaches the saved coverage threshold.
Depth
The strongest recorded connection is to arterial calcification control, with limited coverage.
Breadth
None of the listed processes reaches the saved coverage threshold.
Evidence77
Vitamin K provides the strongest recorded evidence contribution, with benefits limited to the outcomes and populations assessed. The saved assessment treats the evaluated preparations as matching the research preparations.
Evidence strength
Vitamin K provides the strongest recorded evidence contribution, with benefits limited to the outcomes and populations assessed.
Studied preparation
The saved assessment treats the evaluated preparations as matching the research preparations.
Formulation logic100
The evaluated ingredients work alone or have their relevant partners present. All evaluated ingredients reach the saved minimum dose threshold.
Partner coverage
The evaluated ingredients work alone or have their relevant partners present.
Conflicts
No ingredient conflicts were recorded.
Effective doses
All evaluated ingredients reach the saved minimum dose threshold.
Impact
High effect
Vitamin K · 2600 mcgVitamin C · 10 mg
Vitamin K supports activation of proteins involved in bone mineral handling. This serving separately declares 100 mcg of MK-7, alongside K1 and MK-4; their amounts cannot be combined to represent MK-7. MK-7 has limited bone-density evidence in postmenopausal women, with mixed findings and no established general fracture prevention. Its serving amount is below the 180 mcg daily exposure used in one favorable three-year trial.
How this product is rated for Bone Health
Ingredient fit76
MK-7 provides the relevant, focused bone-protein contribution; the small vitamin C amount does not add a meaningful contribution.
Goal fit
The relevant activity centers on MK-7 rather than a broad mixture of unrelated actives.
Dose adequacy
The 100 mcg MK-7 serving provides partial coverage relative to the supplied study anchor; K1 and MK-4 do not increase that amount.
Pathways42
Bone-protein activation is the sole substantially represented route.
Depth
MK-7 supplies the product's bone-protein activation contribution.
Breadth
Only bone-protein activation is substantially represented; mineral supply and calcium absorption are not covered.
Evidence98
The relevant human findings concern MK-7 in postmenopausal women and remain mixed.
Evidence strength
MK-7 supplies the strongest relevant evidence, limited to mixed bone-density findings in postmenopausal women.
Studied preparation
The explicitly declared trans MK-7 matches the relevant preparation; the larger K1 and MK-4 declarations do not establish equivalent evidence.
Formulation logic100
The relevant MK-7 contribution has no unmet partner requirement or identified conflict.
Partner coverage
MK-7 has no unmet partner requirement in the supplied findings.
Conflicts
No configured conflict was identified; the high-vitamin-D condition is inapplicable because vitamin D is absent.
Effective doses
MK-7 reaches the amount threshold used for inclusion; the small vitamin C amount does not.
Impact
Situational effect
Vitamin K · 2600 mcgVitamin C · 10 mg
Impact
Moderate effect
Vitamin K · 2600 mcg
Vitamin K activates proteins relevant to vascular mineral handling. The eligible amount is not summarized as a single confirmed dose here, and the preparation is unidentified; the limited arterial-stiffness evidence for MenaQ7 cannot be assumed to apply to the mixture or to lifespan.
How this product is rated for Longevity
Ingredient fit76
The saved assessment identifies 1 relevant ingredients and no other active ingredients; the formula serves 5 goals. The saved amount assessment is limited overall, with unknown amounts contributing no support.
Goal fit
The saved assessment identifies 1 relevant ingredients and no other active ingredients; the formula serves 5 goals.
Dose adequacy
The saved amount assessment is limited overall, with unknown amounts contributing no support.
Pathways11
Arterial calcification control is the strongest represented mechanism, with partial coverage in the saved findings. 0 of the three mechanism targets meets the saved coverage threshold.
Depth
Arterial calcification control is the strongest represented mechanism, with partial coverage in the saved findings.
Breadth
0 of the three mechanism targets meets the saved coverage threshold.
Evidence25
Vitamin K leads the saved evidence comparison among ingredients meeting the amount threshold. This comparison does not imply uniform aging benefits. The saved evidence match is incomplete for Vitamin K.
Evidence strength
Vitamin K leads the saved evidence comparison among ingredients meeting the amount threshold. This comparison does not imply uniform aging benefits.
Studied preparation
The saved evidence match is incomplete for Vitamin K.
Formulation logic100
The assessed ingredients work alone or have their required partner. No configured conflict was identified. 1 of 1 assessed ingredients meet the saved minimum amount threshold.
Partner coverage
The assessed ingredients work alone or have their required partner.
Conflicts
No configured conflict was identified.
Effective doses
1 of 1 assessed ingredients meet the saved minimum amount threshold.
Impact
High effect
Vitamin K · 2600 mcgVitamin C · 10 mg
Vitamin K as MK-7 has limited evidence for selected arterial-stiffness measures in postmenopausal women. The saved findings recognize an MK-7 preparation, but mixed vitamin K forms and an unresolved parent amount limit interpretation of the MK-7 portion. The small vitamin C declaration does not establish routine cardiovascular prevention or an added combination benefit.
How this product is rated for Cardiovascular Support
Ingredient fit72
The relevant ingredients provide a cardiovascular connection, with their declared amounts determining how closely study exposures can be compared.
Goal fit
The recognized ingredients give the formula a clear cardiovascular focus.
Dose adequacy
Some recognized amounts fall below comparison exposures or remain unresolved, limiting confidence in matching the studied effects.
Pathways19
The findings concentrate on arterial calcification control, rather than establishing broad clinical protection.
Depth
The strongest recorded area is arterial calcification control, with the clinical limits described for the relevant ingredients.
Breadth
No selected pathway reaches the saved breadth threshold.
Evidence69
Evidence recognition concerns the supplied ingredients and preparations; the scientific context preserves distinctions between marker changes and clinical events.
Evidence strength
Vitamin K leads the recognized evidence findings; marker changes and population limits constrain what that means for cardiovascular outcomes.
Studied preparation
The recognized preparation declarations receive a study match in the saved findings; this does not extend their results beyond the studied outcomes and populations.
Formulation logic100
No missing required partner or ingredient conflict is recorded; amount limitations still affect interpretation.
Partner coverage
No required partner is missing for the recognized ingredients; this does not establish extra benefit from combining them.
Conflicts
No ingredient conflict was recorded in the supplied findings.
Effective doses
All recognized ingredients meet the saved minimum amount threshold; this is not a proven clinical-effect threshold.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Vitamin C (Ascorbyl Palmitate) | 10 mg | |
Vitamin K | 2600 mcg |
Vitamin K · 2600 mcg OverallScore100
Each serving provides 100 mcg of trans-MK-7 as part of a wider vitamin K mix. Its amount is separately stated, making it easier to compare with products that give only a total.
How this ingredient is rated
Active Ingredient Quality & Bioavailability100
The saved forms include vitamin K2 as trans-MK-7 along with K1 and MK-4. The MK-7 is identified as trans.
Vitamin K Form (MK-7 vs. MK-4 vs. K1)
The saved forms include vitamin K2 as trans-MK-7 along with K1 and MK-4.
MK-7 Isomer Disclosure
The MK-7 is identified as trans.
Dose, Safety & Label Transparency100
Each serving provides 100 mcg of MK-7. The saved facts separately identify amounts for K1, MK-4 and MK-7.
Vitamin K2 (MK-7) Dosage Efficacy
Each serving provides 100 mcg of MK-7.
Form and Subtype Transparency
The saved facts separately identify amounts for K1, MK-4 and MK-7.
Value100
A whole-product serving costs about $0.25 and provides 100 mcg of MK-7.
Price per Effective MK-7 Serving
A whole-product serving costs about $0.25 and provides 100 mcg of MK-7.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Can Dietary Intake of Vitamin C-Oriented Foods Reduce the Risk of Osteoporosis, Fracture, and BMD Loss? Systematic Review With Meta-Analyses of Recent Studies.
- Dietary vitamin C intake and the risk of hip fracture: a dose-response meta-analysis.
- Smoking, antioxidant vitamins, and the risk of hip fracture.
- Micronutrients and the risk of hip fracture: Case-control study.
- Favorable effect of dietary vitamin C on bone mineral density in postmenopausal women (KNHANES IV, 2009): discrepancies regarding skeletal sites, age, and vitamin D status.
- Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials.
- Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women.
- Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis.
- Efficacy and safety of vitamin K2 for postmenopausal women with osteoporosis at a long-term follow-up: meta-analysis and systematic review.
- Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women.
- Vitamin C may reduce troponin and CKMB levels after PCI and CABG: a meta-analysis.
- Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension.
- Vitamin C supplementation improves blood pressure and oxidative stress after acute exercise in patients with poorly controlled type 2 diabetes mellitus: A randomized, placebo-controlled, cross-over study.
- Vascular benefits of vitamin C supplementation against fine particulate air pollution in healthy adults: A double-blind randomised crossover trial.
- Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes.
- Vitamin K Intake and Atherosclerotic Cardiovascular Disease in the Danish Diet Cancer and Health Study.
- Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial.
- Effects of One-Year Menaquinone-7 Supplementation on Vascular Stiffness and Blood Pressure in Post-Menopausal Women.
- Dietary Vitamin K1 Intake and Incident Aortic Valve Stenosis.
- Association between vitamin K1 intake and mortality in the Danish Diet, Cancer, and Health cohort.